Compositions for treating heartworm infestation
AssigneeCeva Sante Animale
InventorsPatrick Forget, Vassilios Kaltsatos, Stephan Warin
Life of this patent
Estimating the term…
Abstract
The present invention further relates to ivermectin, most preferably formulated as an implant for administration of pet and domestic animals. These formulations provide long term protection against Dirofilaria parasites, without the risks for secondary adverse events of conventional formulations. Preferred formulations are implants and are administered at least twice a year, once a year, or at least once in 18 months, up to 24 months.
Claims21
1-24. (canceled)
A method of controlling heartworm disease, comprising administering to a non-human animal subject a composition comprising an effective dose of ivermectin to control Dirofilaria immitis and/or Dirofilaria repens infestation, wherein said ivermectin composition is in the form of an implant, and said composition is administered at least twice a year, once a year, once in 18 months, or once in 24 months.
A veterinary drug composition for use in controlling heartworm disease or dirofilariose in a non-human animal subject, wherein said composition is in the form of an implant, wherein said composition comprises an effective dose of ivermectin, and is administered at least twice a year, once a year, once in 18 months up to 24 months.
A veterinary drug composition for use in controlling Dirofilaria immitis and/or Dirofilaria repens infestation in non-human animal subject, wherein said composition is in the form of an implant, wherein said composition comprises an effective dose of ivermectin, and is administered at least twice a year, once a year, once in 18 months up to 24 months.
A kit useful in the control of a parasitic infestation of heartworm in a non-human animal subject, which comprises an implant containing an effective dose of ivermectin for controlling Dirofilaria immitis and/or Dirofilaria repens infestation, at a lower plasma concentration of ivermectin of about 5% to 95% as compared to plasma ivermectin concentration obtained via conventional ivermectin formulation, and instructions for the treatment and/or prevention in said subject.
Dependencies are inferred from the claim text.